Assignee
APELLIS PHARMACEUTICALS INC
US·22 granted patents·38 pending applications·90 citations·filing 2013–2025
Top patents by PatentIndex Score
60 records- 0194US10407466B2Methods of selecting compstatin mimeticsAPELLIS PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·12 cites·2 claims
- 0293US11338013B2Combination therapy for C3 inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2017·Granted May 24, 2022·7 cites·19 claims
- 0393US11292815B2Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 5, 2022·2 cites·11 claims
- 0493US11001610B2Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted May 11, 2021·4 cites·23 claims
- 0593US10875893B2Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted Dec 29, 2020·10 cites·9 claims
- 0693US10308687B2Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2014·Granted Jun 4, 2019·14 cites·13 claims
- 0793US10035822B2Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2013·Granted Jul 31, 2018·15 cites·12 claims
- 0892US12290566B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2023·Granted May 6, 2025·2 cites·20 claims
- 0992US11844841B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2021·Granted Dec 19, 2023·4 cites·26 claims
- 1092US11407789B2Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·2 cites·11 claims
- 1188US11040107B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·9 cites·24 claims
- 1288US10941184B2Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2019·Granted Mar 9, 2021·3 cites·11 claims
- 1388US2025282823A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1486US11013782B2Methods of treating chronic disorders with complement inhibitorsAPELLIS PHARMACEUTICALS INC·Filed 2019·Granted May 25, 2021·1 cites·24 claims
- 1585US11510939B1RNAs for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Nov 29, 2022·1 cites·16 claims
- 1685US2026062448A1Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1783US2024076317A1Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1882US11903994B2Dosing regimensAPELLIS PHARMACEUTICALS INC·Filed 2016·Granted Feb 20, 2024·4 cites·10 claims
- 1978US12251395B2RNAS for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2022·Granted Mar 18, 2025·0 cites·7 claims
- 2078US2023091471A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2176US11661441B2Cell-reactive, long-acting, or targeted compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2021·Granted May 30, 2023·0 cites·34 claims
- 2276US2023075121A1Cell-penetrating compstatin analogs and uses thereofAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2375US12528836B2Dosing regimensAPELLIS PHARMACEUTICALS INC·Filed 2023·Granted Jan 20, 2026·0 cites·10 claims
- 2475US11712460B2Methods of treating chronic disorders with complement inhibitorsAPELLIS PHARMACEUTICALS INC·Filed 2021·Granted Aug 1, 2023·0 cites·19 claims
- 2574US2022249663A1Methods and compositions for cancer treatment and treatment selectionAPELLIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2674US2024285783A1Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2773US12458695B2Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2025·Granted Nov 4, 2025·0 cites·30 claims
- 2873US10696718B2Compstatin analogs for treatment of neuropathic painAPELLIS PHARMACEUTICALS INC·Filed 2018·Granted Jun 30, 2020·0 cites·3 claims
- 2971US2020325175A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3070US2021107944A1Compstatin analogs for treatment of neuropathic painAPELLIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3168US2023009757A1Combination therapy for c3 inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3267US11291407B2Detection of high risk drusenAPELLIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 5, 2022·0 cites·7 claims
- 3367US2025075209A1Rnas for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3466US2016194359A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 3565US2017166610A1Compstatin Analogs for Treatment of Neuropathic PainAPELLIS PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3664US2020316163A1Dosing regimens and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3764US2024216538A1Genomic editing of complementAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3864US2025297287A1Compositions and methods for genome editing the neonatal fc receptorAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3964US2020155675A1Methods and compositions for cancer treatment and treatment selectionAPELLIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4064US2025002910A1Treatment of complement-mediated disordersAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4162US2017283461A1Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methodsAPELLIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4262US2015150945A1Modifying Macrophage Phenotype for Treatment of DiseaseAPELLIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4361US2024110182A1Genomic editing of complementAPELLIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4460US2026069653A1Complement inhibitor dosing regimensAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4560US2019192617A1Methods of treating chronic disorders with complement inhibitorsAPELLIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4660US2025000936A1Treatment of geographic atrophyAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4758US2023095695A1Rnas for complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4858US2017246298A1Methods and compositions for cancer treatment and treatment selectionAPELLIS PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4957US2024360103A1Complement inhibitionAPELLIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 5057US2016067357A1Detection of high risk drusenAPELLIS PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 60 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →